**FOI Ref: 6379**

**Category(ies): Clinical - Drugs**

**Subject: Biologic and Biosimilar Products within Rheumatology**

**Date Received: 05/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs: * Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Baricitinib [Olumiant]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Filgotinib [Jyseleca]
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Rituximab [MabThera]
* Rituximab Biosimilars
* Sarilumab [Kevzara]
* Secukinumab [Cosentyx]
* Tocilizumab [Ro Actemra]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]
 | * Abatacept [Orencia] - 32
* Adalimumab [Humira] - 0
* Adalimumab Biosimilars - 0
* Amgevita (Adalimumab) - 130
* Apremilast [Otezla] - 0
* Baricitinib [Olumiant] - 12
* Benepali - 340
* Certolizumab [Cimzia] - 13
* Etanercept [Enbrel] - 6
* Etanercept Biosimilars - 0
* Filgotinib [Jyseleca] - 0
* Golimumab [Simponi] - 10
* Guselkumab [Tremfya] - 0
* Infliximab [Remicade] - 0
* Infliximab Biosimilars - 0
* Ixekizumab [Taltz] - 0
* Metoject – 333
* Risankizumab [Skyrizi] - 0
* Rituximab [MabThera] - 0
* Rituximab Biosimilars - 0
* Sarilumab [Kevzara] - 0
* Secukinumab [Cosentyx] - 19
* Tocilizumab [Ro Actemra] - 34
* Tofacitinib [Xeljanz] - 0
* Upadacitinib [Rinvoq] - 0
* Ustekinumab [Stelara] - 0
 |
| Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.  * Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Secukinumab [Cosentyx]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]
 | We are unable to provide this level of detail as we do not have a clinical data base search function on the Trust EPR system and it would *exceed the appropriate time/cost limit under Section 12(1) of the FOI Act* to manually search. |